J
Jae-Hyung Kim
Researcher at Catholic University of Korea
Publications - 9
Citations - 2276
Jae-Hyung Kim is an academic researcher from Catholic University of Korea. The author has contributed to research in topics: Aspirin & Placebo. The author has an hindex of 6, co-authored 8 publications receiving 1593 citations. Previous affiliations of Jae-Hyung Kim include The Catholic University of America.
Papers
More filters
Journal ArticleDOI
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
John W. Eikelboom,Stuart J. Connolly,Jackie Bosch,Gilles R. Dagenais,Robert G. Hart,Olga Shestakovska,Rafael Diaz,Marco Alings,Eva Lonn,Sonia S. Anand,Petr Widimsky,Masatsugu Hori,Alvaro Avezum,Leopoldo S. Piegas,Kelley R. Branch,Jeffrey L. Probstfield,Deepak L. Bhatt,Jun Zhu,Yan Liang,Aldo P. Maggioni,Patricio Lopez-Jaramillo,Martin O'Donnell,Ajay K. Kakkar,Keith A.A. Fox,Alexander Parkhomenko,Georg Ertl,Stefan Störk,Matyas Keltai,Lars Rydén,Nana Pogosova,Antonio L. Dans,Fernando Lanas,Patrick J. Commerford,Christian Torp-Pedersen,Tomek J. Guzik,Peter Verhamme,Dragos Vinereanu,Jae-Hyung Kim,Andrew Tonkin,Basil S. Lewis,Camilo Felix,Khalid Yusoff,P. Gabriel Steg,Kaj Metsärinne,Nancy Cook Bruns,Frank Misselwitz,Edmond Chen,Darryl P. Leong,Salim Yusuf +48 more
TL;DR: Among patients with stable atherosclerotic vascular disease, those assigned to rivaroxaban (2.5 mg twice daily) plus aspirin had better cardiovascular outcomes and more major bleeding events than those assign to aspirin alone.
Journal ArticleDOI
A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke
Pierre Amarenco,Jae-Hyung Kim,J. Labreuche,Hugo Charles,Jérémie Abtan,Yannick Béjot,Lucie Cabrejo,Cha Jk,Gregory Ducrocq,M Giroud,Céline Guidoux,Hobeanu C,Kim Yj,Bertrand Lapergue,Philippa C. Lavallée,Lee Bc,Lee Kb,Leys D,Mahagne Mh,Elena Meseguer,Nighoghossian N,Fernando Pico,Yves Samson,Igor Sibon,Phillippe Gabriel Steg,Sung Sm,Pierre-Jean Touboul,Emmanuel Touzé,Olivier Varenne,Eric Vicaut,Yelles N,Eric Bruckert +31 more
TL;DR: After an ischemic stroke or TIA with evidence of atherosclerosis, patients who had a target LDL cholesterol level of less than 70 mg per deciliter had a lower risk of subsequent cardiovascular events than those whoHad a target range of 90 mg to 110 mg perDeciliter.
Journal ArticleDOI
Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin
Paul Moayyedi,John W. Eikelboom,Jackie Bosch,Stuart J. Connolly,Leanne Dyal,Olga Shestakovska,Darryl P. Leong,Sonia S. Anand,Stefan Störk,Kelley R. Branch,Deepak L. Bhatt,Peter Verhamme,Martin O'Donnell,Aldo P. Maggioni,Eva Lonn,Leopoldo S. Piegas,Georg Ertl,Matyas Keltai,Nancy Cook Bruns,Eva Muehlhofer,Gilles R. Dagenais,Jae-Hyung Kim,Masatsugu Hori,P. Gabriel Steg,Robert G. Hart,Rafael Diaz,Marco Alings,Petr Widimsky,Alvaro Avezum,Jeffrey L. Probstfield,Jun Zhu,Yan Liang,Patricio Lopez-Jaramillo,Ajay K. Kakkar,Alexander Parkhomenko,Lars Rydén,Nana Pogosova,Antonio L. Dans,Fernando Lanas,Patrick J. Commerford,Christian Torp-Pedersen,Tomek J. Guzik,Tomek J. Guzik,Dragos Vinereanu,Andrew Tonkin,Basil S. Lewis,Camilo Felix,Khalid Yusoff,Kaj Metsärinne,Keith A.A. Fox,Salim Yusuf +50 more
TL;DR: In a large placebo-controlled randomized trial, it is found that pantoprazole is not associated with any adverse event when used for 3 years, with the possible exception of an increased risk of enteric infections.
Journal ArticleDOI
Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial.
Paul Moayyedi,John W. Eikelboom,Jackie Bosch,Stuart J. Connolly,Leanne Dyal,Olga Shestakovska,Darryl P. Leong,Sonia S. Anand,Stefan Störk,Kelly R.H. Branch,Deepak L. Bhatt,Peter Verhamme,Martin O'Donnell,Aldo P. Maggioni,Eva Lonn,Eva Lonn,Leopoldo S. Piegas,Georg Ertl,Matyas Keltai,Nancy Cook Bruns,Eva Muehlhofer,Gilles R. Dagenais,Jae-Hyung Kim,Masatsugu Hori,P. Gabriel Steg,Robert G. Hart,Rafael Diaz,Marco Alings,Petr Widimsky,Alvaro Avezum,Jeffrey L. Probstfield,Jun Zhu,Yan Liang,Patricio Lopez-Jaramillo,Ajay K. Kakkar,Alexander Parkhomenko,Lars Rydén,Nana Pogosova,Antonio L. Dans,Fernando Lanas,Patrick J. Commerford,Christian Torp-Pedersen,Tomek J. Guzik,Tomek J. Guzik,Dragos Vinereanu,Andrew Tonkin,Basil S. Lewis,Camilo Felix,Khalid Yusoff,Kaj Metsärinne,Keith A.A. Fox,Salim Yusuf +51 more
TL;DR: Routine use of proton pump inhibitors in patients receiving low-dose anticoagulation and/or aspirin for stable cardiovascular disease does not reduce upper gastrointestinal events but may reduce bleeding from gastroduodenal lesions.
Journal ArticleDOI
Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial.
Mukul Sharma,Robert G. Hart,Eric E. Smith,Jackie Bosch,Jackie Bosch,Fei Yuan,Amparo Casanova,John W. Eikelboom,Stuart J. Connolly,Gloria Wong,Rafael Diaz,Patricio Lopez-Jaramillo,Georg Ertl,Stefan Störk,Gilles R. Dagenais,Eva Lonn,Lars Rydén,Andrew Tonkin,John Varigos,Deepak L. Bhatt,Kelley Rh Branch,Jeffrey L. Probstfield,Jae-Hyung Kim,Jong-Won Ha,Martin O'Donnell,Dragos Vinereanu,Keith A.A. Fox,Yan Liang,Lisheng Liu,Jun Zhu,Nana Pogosova,Aldo P. Maggioni,Alvaro Avezum,Leopoldo S. Piegas,Katalin Keltai,Matyas Keltai,Nancy Cook Bruns,Scott D. Berkowitz,Salim Yusuf +38 more
TL;DR: Demonstration of a therapeutic effect of the antithrombotic regimens on brain infarcts would have implications for prevention of cognitive decline and provide insight into the pathogenesis of vascular cognitive decline.